...
aclx-img

Arcellx Inc, Common Stock

ACLX

NSQ

$77.535

-$4.49

(-5.47%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$4.44B
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
196.98K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.27
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$47.88 L
$107.37 H
$77.535

About Arcellx Inc, Common Stock

Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company's preclinical product includes ACLX-003 for the treatment of AML and MDS. Further, it focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize anitocabtagene autoleucel. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameACLXSectorS&P500
1-Week Return-0.3%-3.39%0.2%
1-Month Return-7.02%-1.92%2.72%
3-Month Return5.17%-10.54%7.31%
6-Month Return52.6%-4.47%10.44%
1-Year Return64.91%4.06%27.53%
3-Year Return388.24%0.94%30.88%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue---17.91M110.32M[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":16.24,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Cost of Revenue326.00K629.00K1.04M2.22M2.04M[{"date":"2019-12-31","value":14.66,"profit":true},{"date":"2020-12-31","value":28.28,"profit":true},{"date":"2021-12-31","value":46.81,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":91.73,"profit":true}]
Gross Profit(326.00K)(629.00K)(1.04M)(2.22M)110.32M[{"date":"2019-12-31","value":-0.3,"profit":false},{"date":"2020-12-31","value":-0.57,"profit":false},{"date":"2021-12-31","value":-0.94,"profit":false},{"date":"2022-12-31","value":-2.02,"profit":false},{"date":"2023-12-31","value":100,"profit":true}]
Gross Margin---(12.42%)100.00%[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":-12.42,"profit":false},{"date":"2023-12-31","value":100,"profit":true}]
Operating Expenses17.97M32.10M65.02M191.26M200.20M[{"date":"2019-12-31","value":8.98,"profit":true},{"date":"2020-12-31","value":16.03,"profit":true},{"date":"2021-12-31","value":32.48,"profit":true},{"date":"2022-12-31","value":95.53,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Income(17.97M)(32.10M)(65.02M)(191.26M)(89.88M)[{"date":"2019-12-31","value":-1797400000,"profit":false},{"date":"2020-12-31","value":-3209600000,"profit":false},{"date":"2021-12-31","value":-6501800000,"profit":false},{"date":"2022-12-31","value":-19125900000,"profit":false},{"date":"2023-12-31","value":-8988000000,"profit":false}]
Total Non-Operating Income/Expense--98.00K5.16M35.25M[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":0.28,"profit":true},{"date":"2022-12-31","value":14.64,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Pre-Tax Income(17.97M)(32.09M)(64.97M)(188.68M)(70.03M)[{"date":"2019-12-31","value":-1797200000,"profit":false},{"date":"2020-12-31","value":-3209500000,"profit":false},{"date":"2021-12-31","value":-6496900000,"profit":false},{"date":"2022-12-31","value":-18867900000,"profit":false},{"date":"2023-12-31","value":-7002700000,"profit":false}]
Income Taxes(2.00K)422.70K(1.04M)(2.58M)663.00K[{"date":"2019-12-31","value":-0.3,"profit":false},{"date":"2020-12-31","value":63.76,"profit":true},{"date":"2021-12-31","value":-157.01,"profit":false},{"date":"2022-12-31","value":-389.14,"profit":false},{"date":"2023-12-31","value":100,"profit":true}]
Income After Taxes--(63.93M)(186.10M)(70.69M)[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":-6392800000,"profit":false},{"date":"2022-12-31","value":-18609900000,"profit":false},{"date":"2023-12-31","value":-7069000000,"profit":false}]
Income From Continuous Operations(17.97M)(32.09M)(64.97M)(188.68M)(129.53M)[{"date":"2019-12-31","value":-1797200000,"profit":false},{"date":"2020-12-31","value":-3209500000,"profit":false},{"date":"2021-12-31","value":-6496900000,"profit":false},{"date":"2022-12-31","value":-18867900000,"profit":false},{"date":"2023-12-31","value":-12952600000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(17.97M)(32.09M)(63.93M)(186.10M)(70.69M)[{"date":"2019-12-31","value":-1797200000,"profit":false},{"date":"2020-12-31","value":-3209500000,"profit":false},{"date":"2021-12-31","value":-6392800000,"profit":false},{"date":"2022-12-31","value":-18609900000,"profit":false},{"date":"2023-12-31","value":-7069000000,"profit":false}]
EPS (Diluted)--(39.85)(5.32)(1.47)[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":-3985,"profit":false},{"date":"2022-12-31","value":-532,"profit":false},{"date":"2023-12-31","value":-147,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

ACLX
Cash Ratio 4.19
Current Ratio 4.29

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

ACLX
ROA (LTM) -6.29%
ROE (LTM) -10.79%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

ACLX
Debt Ratio Lower is generally better. Negative is bad. 0.37
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.63

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

ACLX
Trailing PE NM
Forward PE NM
P/S (TTM) 28.47
P/B 9.18
Price/FCF 156
EV/R 25.20
EV/Ebitda NM

FAQs

What is Arcellx Inc share price today?

Arcellx Inc (ACLX) share price today is $77.535

Can Indians buy Arcellx Inc shares?

Yes, Indians can buy shares of Arcellx Inc (ACLX) on Vested. To buy Arcellx Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in ACLX stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Arcellx Inc be purchased?

Yes, you can purchase fractional shares of Arcellx Inc (ACLX) via the Vested app. You can start investing in Arcellx Inc (ACLX) with a minimum investment of $1.

How to invest in Arcellx Inc shares from India?

You can invest in shares of Arcellx Inc (ACLX) via Vested in three simple steps:

  • Click on Sign Up or Invest in ACLX stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Arcellx Inc shares
What is Arcellx Inc 52-week high and low stock price?

The 52-week high price of Arcellx Inc (ACLX) is $107.37. The 52-week low price of Arcellx Inc (ACLX) is $47.88.

What is Arcellx Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Arcellx Inc (ACLX) is

What is Arcellx Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Arcellx Inc (ACLX) is 9.18

What is Arcellx Inc dividend yield?

The dividend yield of Arcellx Inc (ACLX) is 0.00%

What is the Market Cap of Arcellx Inc?

The market capitalization of Arcellx Inc (ACLX) is $4.44B

What is Arcellx Inc’s stock symbol?

The stock symbol (or ticker) of Arcellx Inc is ACLX

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top